NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)